Page 2496 - Williams Hematology ( PDFDrive )

2467
2466 Index Index 2467

Monocytoma. See Myeloid (granulocytic) in myelofibrosis, 229t Mucosa-associated lymphoid tissue (MALT),
sarcoma in primary myelofibrosis, 1321 93–94. See also Extranodal
Monocytopenia, 1089 in refractory anemia with ring marginal zone lymphoma of MALT
clinical features, 1091 sideroblasts with thrombocytosis, type
consultative approach to, 42 1352 Mucosal addressin cell adhesion molecule 1
disorders associated with, 1090t, 1098, MPLV (myeloproliferative leukemia virus), (MAdCAM-1), 950, 1977
1098t 1822 Mucositis, 368
Monocytopoiesis, in newborn, 105 MPO (myeloperoxidase), 107, 1011, 1012t, Mucous membrane hemorrhage, 2120
Monocytosis 1068f μ-heavy-chain disease, 1809–1810, 1810f
classification, 1089, 1090t MPO (myeloperoxidase) deficiency, 1020t, Multidrug resistance, 318
consultative approach to, 44 1033 Multidrug resistance-associated proteins
disorders associated with, 1095–1097, M-proteins, 1714, 1723, 1741 (MRPs), 318
1096t MPS (mononuclear phagocyte system), Multimerin, 1845, 1846t, 1924
tissue effects, 1092 1045, 1046t. See also Macrophages; Multiparameter flow cytometry (MPC), 1716
Monoferric transferrin pool, 491 Monocytes Multiple intestinal atresia, 1222
MonoMAC syndrome, 1089, 1098, 1231, MPV (mean platelet volume), 17 Multiple myeloma. See Myeloma
1351, 1379 MRD. See Minimal residual disease (MRD) Multiple sclerosis, 1265, 2239
Monomethoxypolyethylene glycol (PEG), 332 MRI. See Magnetic resonance imaging (MRI) Multipotential cells
Mononeuritis multiplex, 959 mRNA (messenger RNA) embryonic stem cells, 448–449
Mononuclear phagocyte system (MPS), globin gene clusters regulation and, hematopoietic stem cells. See
1045, 1046t. See also Macrophages; 729–730 Hematopoietic stem cells (HSCs)
Monocytes mutations causing abnormal translation of, induced pluripotent stem cells, 449
Mononucleosis syndromes, 1261–1269 731–732, 732f leukemia stem cell, 1376
autoimmune hemolytic anemia and, 824, platelet, 1851–1853, 1852f mesenchymal stromal cells, 449–450
835 in protein synthesis, 147 for tissue repair. See Multipotential cell
cytomegalovirus. See Cytomegalovirus von Willebrand factor, 2164, 2165f therapy
(CMV) mononucleosis MRP-1. See CD9 Multipotential cell therapy
definition and history, 1261 MRP-14 (S100A9), 1856, 1872 for brain and spinal cord repair, 451–452
differential diagnosis, 1269, 1513 MRPs (multidrug resistance-associated for cardiac repair, 450
Epstein-Barr virus. See Epstein-Barr virus proteins), 318 gene edited cells in, 453–454
(EBV) mononucleosis MRs (mannose receptors), 284, 1054, 1057t, for liver and pancreas repair, 452–453
etiology and pathogenesis, 1261, 1262t 1080, 1081f for lung repair, 451
Hodgkin lymphoma and, 1605 MRSA (methicillin-resistant Staphylococcus principles, 447, 448f
neutropenia and, 997 aureus) infections, 384–385 Multispecies conserved sequences (MCSs),
in pregnancy, 1269 MSCs (mesenchymal stromal cells), 449–450, 730
in primary HIV infection, 1268 451 Multivesicular bodies (MVBs), 1844
therapy, 1269 MTA (5′-deoxy-5′[methylthio] adenosine), MUNC13-4 (Munc13–4), 1114, 1849
Monophosphoglyceromutase, 692t 239 Muramyl dipeptide (MDP), 299, 301f
Monosomy 7, 521, 1347 MTA (metastasis-associated), 166 Murine double minute protein 2 (MDM2),
MOPP regimen, for Hodgkin lymphoma, MTA3, 166 238
1604, 1611, 1617, 1618 MTAP (methylthioadenosine Murine stem cells, assays of, 259
Morbus caeruleus, 871 phosphorylase), 238–239 Muscular function, iron deficiency and, 631
Morphine, 767–768 MTHFR Mutasome, 1169
Morula (Mott) cell, 1742, 1743f colon cancer and, 599 MY01G, 414
Mountain sickness, 875, 881 hyperhomocysteinemia and, 599, 2224. MYBL2, 1347–1348
Mouth See also Hyperhomocysteinemia MYC
examination, 8 MTHFR (methylenetetrahydrofolate activation, 194–195, 194f, 195f
history of dryness of, 5 reductase), 585, 590 functions, 187, 192
6-MP. See 6-Mercaptopurine (6-MP) MTHFR (methylenetetrahydrofolate in myeloma, 200
MPC (multiparameter flow cytometry), 1716 reductase) deficiency, 608 MYC/Myc, 1576
M-phase promoting factors, 213 mTOR (mammalian target of rapamycin), in Burkitt lymphoma, 1245, 1672, 1674
MPL, 519 194, 1654, 2237, 2237f in diffuse large B-cell lymphoma, 1626,
in acute megakaryoblastic leukemia, 1392 mTOR (mammalian target of rapamycin) 1627t, 1632–1633
in essential thrombocythemia, 229t, 1307, inhibitors, 1220, 1403. See also in “double-hit” lymphoma, 1502, 1596,
1308f, 1310 Temsirolimus 1633, 1674
in familial thrombocytosis, 1310 Mucopolysaccharidoses, 23 in myeloma, 1709, 1711, 1735, 1735f, 1736

Kaushansky_index_p2393-2506.indd 2467 9/21/15 3:22 PM